|Other Names||CX3C chemokine receptor 1, C-X3-C CKR-1, CX3CR1, Beta chemokine receptor-like 1, CMK-BRL-1, CMK-BRL1, Fractalkine receptor, G-protein coupled receptor 13, V28, CX3CR1, CMKBRL1, GPR13|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for the CX3C chemokine fractalkine (CX3CL1); binds to CX3CL1 and mediates both its adhesive and migratory functions (PubMed:9390561, PubMed:23125415). Acts as coreceptor with CD4 for HIV-1 virus envelope protein (in vitro) (PubMed:9726990). Isoform 2 and isoform 3 seem to be more potent HIV-1 coreceptors than isoform 1 (PubMed:14607932).|
|Cellular Location||Cell membrane; Multi-pass membrane protein|
|Tissue Location||Expressed in lymphoid and neural tissues.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Fractalkine is a transmembrane protein and chemokineinvolved in the adhesion and migration of leukocytes. The proteinencoded by this gene is a receptor for fractalkine. The encodedprotein also is a coreceptor for HIV-1, and some variations in thisgene lead to increased susceptibility to HIV-1 infection and rapidprogression to AIDS. Four transcript variants encoding twodifferent isoforms have been found for this gene. [provided byRefSeq].
Karlmark, K.R., et al. Hepatology 52(5):1769-1782(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Yang, X., et al. Br J Ophthalmol 94(9):1211-1214(2010)Sezgin, E., et al. J. Acquir. Immune Defic. Syndr. 54(4):343-351(2010)Staniland, A.A., et al. J. Neurochem. 114(4):1143-1157(2010)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.